Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Olanzapine in the Treatment of Patients With Bipolar I Disorder, Depressed: A Randomized, Double-Blind Comparison With Placebo

NCT00510146 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00510146
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00510146 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Olanzapine in the Treatment of Patients With Bipolar I Disorder, Depressed: A Randomized, Double-Blind Comparison With Placebo
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2007
Completion date
July 31, 2010
Enrollment
514 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

depression, bipolar